Whole Grain Consumption and Body Mass Index in Adult Women: An Analysis of NHANES 1999-2000 and the USDA Pyramid Servings Database

Journal of the American College of Nutrition

Volumn 27, Issue 1, 2008, Pages 80-87

  Good, Carolyn K ^a   Albertson, Ann M ^a   Eldridge, Alison L ^a   Holschuh, Norton ^b  

^a General Mills Bell Institute of Health and Nutrition   (United States)

^b GENERAL MILLS INC   (United States)

Author keywords

Body mass index; NHANES; Whole grain

Indexed keywords

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALORIC INTAKE; CIGARETTE SMOKING; CONTROLLED STUDY; DIETARY INTAKE; EDUCATIONAL STATUS; ETHNICITY; FEMALE; GRAIN; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PHYSICAL ACTIVITY; WAIST CIRCUMFERENCE;

ADULT; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; CEREALS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NUTRITION POLICY; NUTRITION SURVEYS; OBESITY; OVERWEIGHT; WAIST-HIP RATIO;

EID: 42649092557     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2008.10719678     Document Type: Article

References (36)

1. Lardus O, Knetsch AM, Blleumink GS, Deckers KW, Hofman A, Stricker BJ, Witteman JC: C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 152: 514-520, 2006.
2. Tuomisto K, Jousilahti P, Sundvall, J, Pajunen P, Salomaa V: C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 95: 511-518, 2006.
3. Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, Cook TD, Edwards D, Pfeffer MA: Investigators in the Weekly Intervention with Zithromax for Athersclerosis and its Related Disorder study. Am Heart J 152: 298-304, 2006.
4. de Ferranti S, Rifai N: C-reactive protein and cardiovascular disese: a review of risk prediction and interventions. Clin Chim Acta 328: 1-15, 2002.
5. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereuz RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV: C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112: 1289-1295, 2005.
6. Wilson PW, Nam BH, Pencina M, D'Agostino RB SR, Benjamin EJ, O'Donnell CJ: C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165: 2473-2478, 2005.
7. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R; for the Multiple Risk Factor Intervention Trial Research Group: Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 195: 122-128, 2006.
8. Adult Treatment Panel III: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 285: 2486-2497, 2001.
9. Marcovina S, Packard CJ: Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 259: 437-446, 2006.
10. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Sisheng L: Effect of potentially modifiable risk factors associated with myocardial infarctin in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937-952, 2004.
11. Meisinger C, Loewel H, Mraz W, Koenig W: Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 26: 271-278, 2005.
12. Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture P, De Graaf, J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/tencountry panel. J Intern Med 259: 247-258, 2006.
13. Kim HK, Chang SA, Choi EK, Kim YJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS: Association between plasma lipids, and apoliproteins and coronary artery disease: a crosssectional study in a low-risk Korean population. Int J Cardiol 101: 435-440, 2005.
14. Walldius G, Junger N: The apo B/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of evidence. J Int Med 259: 493-519, 2006.
15. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex CAPS). Circulation 101: 477-484, 2000.
16. Walldius G, Jungner I, Holme I, Aastvelt AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026-2033, 2001.
17. Faergeman O: Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease. J Intern Med 259: 434-436, 2006.
18. Blue Cross Blue Shield: Apolipoprotein B Testing for the Diagnosis and Management of Cardiovascular Disease. Medical Policy Reference Manual. Blue Cross of Idaho, 2005.
19. Denke MA: Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112: 3368-3370, 2005.
20. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85: 37-45, 1992.
21. Natarajan S, Glick H, Criqui M, Horowitz D, Lipsitz SR, Kinosian B: Cholesterol measures to identify and treat individuals at risk for coronary heart disease. Am J Prev Med 25: 50-57, 2003.
22. Kannel WB: Risk stratification of dyslipidemia: Insights from the Framingham Study. Curr Med Chem Cardiovasc Hematol Agents 3: 187-193, 2005.
23. Walldius G, Jungner I: Rationale for using apoliprotein B and apolipoprotein A-1 as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 26: 210-212, 2005.
24. Cullen P, Schulte H, Assmann G: The Munster Heart Study (PROCAM) Total Mortality in Middle-Aged Men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 96: 2128-2136, 1997.
25. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol apolipoproteins and the risk of myocardial infarction. N Engl J Med 325: 373-381, 1991.
26. Gaziano JM, Hennekens, CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96: 2520-2525, 1997.
27. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbs SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER Study Group: Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112: 3058-3065, 2005.
28. Gaziano JM, Hennekens, CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96: 2520-2525, 1997.
29. Greene CM, Zern TL, Wood RJ, Shrestha S, Aggarwal D, Sharman MJ, Volek JS, Fernandez ML: Maintenance of the LDL cholesterol: HDL cholesterol ratio in an elderly population given a dietary cholesterol challenge. J Nutr 135: 2793-2798, 2005.
30. Herron KJ, Vega-Lopez S, Conde K, Ramjiganesh T, Roy S, Shachter N, Fernandez ML: Pre-menopausal women classified as hypo-or hyper-responders, do not alter their LDL/HDL ratio following a high dietary cholesterol challenge. J Am Coll Nutr 21: 250-258, 2002.
31. McNamara DJ: The impact of egg limitations on coronary heart disease risk: Do the numbers add up? J Am Coll Nutr 19: 540S-548S, 2000.
32. Fernandez ML: Dietary cholesterol provided by eggs and plasma lipoproteins in healthy populations. Curr Opin Clin Nutr Metab Care 9: 8-12, 2006.
33. Herron KL, Lofgren IE, Sharman M, Volek JS, Fernandez ML: High intake of cholesterol results in less atherogenic low-density lipoprotein particles in men and women independent of response classification. Metabolism 53: 823-830, 2004.
34. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 1917-1921, 1988.
35. Greene CM, Waters D, Clark RM, Contois JH, Fernandez ML: Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population. Nutr Metab (Lond) 3: 6, 2006.
36. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112: 3375-3383, 2005.